货号:A189385
同义名:
3'-Methylquercetin; 3'-O-methyl Quercetin
Isorhamnetin是一种天然的黄酮醇苷,能够抑制黄嘌呤氧化酶,IC50 为 400 nM,并稳定 β-连环蛋白,促进 Wnt 信号通路的上调。Isorhamnetin 还可作为抗肿瘤的凋亡诱导剂。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | MEK ↓ ↑ | MEK1 ↓ ↑ | MEK1/2 ↓ ↑ | MEK2 ↓ ↑ | MEK5 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Honokiol | ✔ | 98% | |||||||||||||||||
| Mirdametinib |
++++
MEK, IC50: 0.33 nM |
99%+ | |||||||||||||||||
| Binimetinib |
+++
MEK, IC50: 12 nM |
99%+ | |||||||||||||||||
| BI-847325 |
++
MEK1, IC50: 25 nM |
+++
MEK2, IC50: 4 nM |
99%+ | ||||||||||||||||
| U0126-EtOH |
+
MEK1, IC50: 0.07 μM |
++
MEK2, IC50: 0.06 μM |
98% | ||||||||||||||||
| GDC-0623 |
++++
MEK1, IC50: 0.13 nM |
99%+ | |||||||||||||||||
| TAK-733 |
++++
MEK1, IC50: 3.2 nM |
99%+ | |||||||||||||||||
| Trametinib |
++++
MEK1, IC50: 0.92 nM |
++++
MEK2, IC50: 1.8 nM |
99%+ | ||||||||||||||||
| Selumetinib |
+++
MEK1, IC50: 14 nM MEK1, Kd: 99 nM |
+
MEK2, Kd: 530 nM |
99%+ | ||||||||||||||||
| CI-1040 |
++
MEK1, IC50: 17 nM |
++
MEK2, IC50: 17 nM |
99%+ | ||||||||||||||||
| Myricetin | ✔ | 98% | |||||||||||||||||
| Refametinib |
++
MEK1, IC50: 19 nM |
++
MEK2, IC50: 47 nM |
99%+ | ||||||||||||||||
| Cobimetinib |
+++
MEK1, IC50: 4.2 nM |
99%+ | |||||||||||||||||
| PD98059 |
+
MEK1, IC50: 2 μM |
99%+ | |||||||||||||||||
| SL327 |
+
MEK1, IC50: 0.18 μM |
+
MEK2, IC50: 0.22 μM |
AP-1 | 98+% | |||||||||||||||
| PD318088 | ✔ | 99% | |||||||||||||||||
| AZD8330 |
+++
MEK1/2, IC50: 7 nM |
99%+ | |||||||||||||||||
| Pimasertib | 98% | ||||||||||||||||||
| (E/Z)-BIX02189 |
++++
MEK5, IC50: 1.5 nM |
99%+ | |||||||||||||||||
| (E/Z)-BIX02188 |
+++
MEK5, IC50: 4.3 nM |
99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Isorhamnetin, a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L., is well known for its anti-inflammatory, anti-oxidative, anti-adipogenic, anti-proliferative, and anti-tumor activities. Isorhamnetin could inhibit cardiac hypertrophy and fibrosis 8 weeks after aortic banding. In vitro studies performed in neonatal rat cardiomyocytes confirmed that isorhamnetin could attenuate cardiomyocyte hypertrophy induced by angiotensin II, which was associated with phosphatidylinositol 3-kinase-AKT signaling pathway[3]. Isorhamnetin inhibited epidermal growth factor (EGF)-induced neoplastic cell transformation. Isorhamnetin attenuated EGF-induced COX-2 expression in JB6 and A431 cells. In an in vivo mouse xenograft using A431 cells, isorhamnetin reduced tumor growth and COX-2 expression[4]. Isorhamnetin inhibits the proliferation of numerous breast cancer cells (IC50, ~10 µM), including MCF7, T47D, BT474, BT-549, MDA-MB-231 and MDA-MB-468, whereas less inhibitory activity is observed in the MCF10A normal breast epithelial cell line (IC50, 38 µM) [5]. Isorhamnetin inhibits the TGF-β/Smad signaling pathway and relieves oxidative stress, thus inhibiting HSC (hepatic stellate cells) activation and preventing liver fibrosis[6]. |
| Concentration | Treated Time | Description | References | |
| Human amniotic epithelial stem cells | 20 µM | 10 days | Investigate the gene expression profile of ISO in hAESCs, showing significant suppression of TGF-β, collagen-related functions, and inflammatory processes | Front Cell Dev Biol. 2020 Sep 29;8:578197. |
| Human amnion epithelial cells (hAECs) | 20 mM | 10 days | Induced hepatic-lineage specific differentiation in hAECs, activating essential biological processes, molecular functions, and signaling pathways for hepatic differentiation. | Front Cell Dev Biol. 2020 Nov 5;8:578036. |
| Porcine ovarian granulosa cells | 20 µM | 24 hours | To investigate the therapeutic effect of isorhamnetin on ZEA-induced damage in porcine ovarian granulosa cells and elucidate its molecular mechanism. Results showed that isorhamnetin suppressed ZEA-induced apoptosis, endoplasmic reticulum stress, and oxidative stress via the PI3K/Akt signaling pathway, promoting cell proliferation and hormone secretion. | Anim Nutr. 2022 Aug 8;11:381-390. |
| Bovine endometrial epithelial cells (bEECs) | 2.5 µM | 24 hours | To evaluate the protective effect of isorhamnetin on NEFA-induced cell damage. Results showed that isorhamnetin significantly improved cell viability, reduced apoptosis, and decreased the expression of BAX and cleaved caspase-3. | Antioxidants (Basel). 2025 Jan 28;14(2):156. |
| BV2 microglial cells | 0, 50, 100, 200 µM | 24 hours | To evaluate the effect of isorhamnetin on LPS-induced inflammatory responses, results showed that isorhamnetin significantly suppressed LPS-induced secretion of NO and PGE2 without significant cytotoxicity. | Int J Mol Med. 2019 Feb;43(2):682-692. |
| NOZ cells | 0, 40, 60, 80, 100 µM | 24, 48, 72 hours | Isorhamnetin significantly inhibited the proliferation of NOZ cells in a time- and dose-dependent manner | Front Pharmacol. 2021 Feb 17;12:628621. |
| GBC-SD cells | 0, 40, 60, 80, 100 µM | 24, 48, 72 hours | Isorhamnetin significantly inhibited the proliferation of GBC-SD cells in a time- and dose-dependent manner | Front Pharmacol. 2021 Feb 17;12:628621. |
| Porcine oocytes | 5, 10, 20, 30 µM | 44 hours | To investigate the protective effect of isorhamnetin on ZEA-induced damage in porcine oocytes. Results showed that isorhamnetin significantly increased the polar body extrusion rate of ZEA-exposed oocytes and inhibited ZEA-induced early apoptosis. | J Anim Sci Biotechnol. 2023 Feb 3;14(1):22. |
| Corneal epithelial cells (CorE) and conjunctival epithelial cells (ConjE) | 30 µM | 48 hours | The cytotoxic effect of isorhamnetin was evaluated, showing that isorhamnetin at 30 μM did not affect cell viability. | Int J Mol Sci. 2021 Apr 12;22(8):3954. |
| CD274-knockout U27 cells (U27−/−) | 10, 20, 40 µM | 48 hours | Reduced sensitivity to ISO, weaker inhibition of migration and invasion | Int J Mol Sci. 2024 Jan 4;25(1):670. |
| Canine mammary tumor U27 cells | 10, 20, 40 µM | 48 hours | Inhibited cell migration and invasion, induced apoptosis | Int J Mol Sci. 2024 Jan 4;25(1):670. |
| Human bladder cancer T24 cells | 127.86 µM (IC50) | 48 hours | Isorhamnetin inhibited T24 cell proliferation via G2/M phase arrest and apoptosis, accompanied by decreased expression of Wee1 and cyclin B1, increased expression of p21WAF1/CIP1, and enhanced binding of p21 to Cdk1. | Cancers (Basel). 2019 Oct 4;11(10):1494. |
| Primary pancreatic acinar cells | 10 µM | 50 minutes | To evaluate the protective effect of isorhamnetin on STC-induced acinar cell necrosis, results showed that isorhamnetin significantly alleviated STC-induced acinar cell necrosis | Int J Mol Sci. 2024 Mar 28;25(7):3784. |
| FRT cells | 30 µM | The effect of isorhamnetin on CFTR chloride channel activity was measured, showing that isorhamnetin fully activated CFTR at 30 μM. | Int J Mol Sci. 2021 Apr 12;22(8):3954. | |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c nude mice | NOZ cell xenograft model | Intraperitoneal injection | 1 or 5 mg/kg | Once daily for 14 days | Isorhamnetin significantly inhibited tumor growth in a dose-dependent manner | Front Pharmacol. 2021 Feb 17;12:628621. |
| C57 mice | Bleomycin-induced pulmonary fibrosis model | Intragastrically | 10 and 30 mg/kg | Once a day for 28 days | To investigate the effect of Isor on bleomycin-induced pulmonary fibrosis. Results showed that Isor attenuated fibrotic changes, reduced collagen deposition and α-SMA expression, and alleviated EMT and ERS. | Int J Mol Med. 2019 Jan;43(1):117-126 |
| C57BL/6 mice | STC or L-arginine-induced SAP model | Intraperitoneal injection | 10 mg/kg or 30 mg/kg | 24 hours or 72 hours after a single injection | To evaluate the protective effect of isorhamnetin on SAP, results showed that isorhamnetin significantly alleviated pancreatic damage and reduced serum lipase and amylase levels | Int J Mol Sci. 2024 Mar 28;25(7):3784. |
| Nude mice | Ishikawa cell xenograft model | Intraperitoneal injection | 20 mg/kg | Once daily for 15 days | Isorhamnetin significantly inhibited the growth of Ishikawa xenografts with an inhibition rate up to 50.42%, and suppressed tumor growth by regulating key proteins of mitochondrial and endoplasmic reticulum-related pathways. | Foods. 2022 Oct 28;11(21):3415 |
| CD-1 mice | Scopolamine-induced dry eye model | Topical ocular administration | 30 μM | Three times a day for 10 days | The therapeutic effect of isorhamnetin on dry eye disease was evaluated, showing that isorhamnetin significantly reduced corneal damage and increased tear volume. | Int J Mol Sci. 2021 Apr 12;22(8):3954. |
| C57BL/6 mice | Angiotensin II-induced cardiac hypertrophy and fibrosis model | Intraperitoneal injection | 5 mg/kg | Once daily for 3 weeks | Investigate the protective effect of ISO on Angiotensin II-induced cardiac hypertrophy and fibrosis, showing significant suppression of myocardial hypertrophy and fibrosis | Front Cell Dev Biol. 2020 Sep 29;8:578197. |
| BALB/SCID nude mice | U27 cell xenograft model | Intraperitoneal injection | 50 mg/kg | Every 3 days for 9 days | Inhibited tumor growth, reduced tumor volume and mass | Int J Mol Sci. 2024 Jan 4;25(1):670. |
| Caenorhabditis elegans | Wild-type and mutant C. elegans | Liquid media | 50-200 μM | 2 days | Isorhamnetin reduced fat accumulation dependent on nhr-49, a functional homolog of PPARα, by upregulating an NHR-49 downstream target (ech-1.1) involved in fatty acid β-oxidation in C. elegans. | Curr Res Food Sci. 2019 Nov 21;2:70-76 |
| C57BL/6 mice | Aspergillus fumigatus keratitis model | Topical administration | 80 μg/mL | Four times per day for 1 to 5 days | To evaluate the antifungal and anti-inflammatory effects of isorhamnetin in a Mice model of A. fumigatus keratitis. Results showed that isorhamnetin treatment alleviated the severity of FK by reducing corneal fungal load and inhibiting neutrophil recruitment and inflammatory factor expression. | Invest Ophthalmol Vis Sci. 2021 Mar 1;62(3):38 |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02627547 | Healthy | Not Applicable | Completed | - | United Kingdom ... 展开 >> University of Glasgow School of Medicine Glasgow, United Kingdom 收起 << |
| NCT02425436 | Intrauterine Growth Restrictio... 展开 >>n (IUGR) 收起 << | Phase 2 | Completed | - | - |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
3.16mL 0.63mL 0.32mL |
15.81mL 3.16mL 1.58mL |
31.62mL 6.32mL 3.16mL |
|
| CAS号 | 480-19-3 |
| 分子式 | C16H12O7 |
| 分子量 | 316.26 |
| SMILES Code | O=C1C(O)=C(C2=CC=C(O)C(OC)=C2)OC3=CC(O)=CC(O)=C13 |
| MDL No. | MFCD00017310 |
| 别名 | 3'-Methylquercetin; 3'-O-methyl Quercetin; Quercetin; 4H-1-Benzopyran-4-one, 2-(3-methoxy-4-hydroxyphenyl)-3,5,7-trihydroxy-; Isorhamnetol; 3'-Methoxyquercetin; 3-methylquercetin |
| 运输 | 蓝冰 |
| InChI Key | IZQSVPBOUDKVDZ-UHFFFAOYSA-N |
| Pubchem ID | 5281654 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(332 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1